TY - JOUR
T1 - Understanding bacterial biofilms in patients with cystic fibrosis
T2 - current and innovative approaches to potential therapies
AU - Høiby, Niels
PY - 2002/12
Y1 - 2002/12
N2 - Chronic P. aeruginosa infection is characterized by production of mucoid alginate and formation of microcolonies (biofilm) as seen in the lungs of cystic fibrosis patients. Oxygen radicals produced by the inflammatory response polymorphonuclear leucocytes induces the alginate production. The biofilm mode of growth is the survival strategy of environmental bacteria and alginate biofilms are also protected against antibiotics and against the immune response in the lungs of the patient. Quorum sensing is important for early and mature biofilm formation and also for the severity of the infection. The new knowledge of the mechanisms involved in biofilm formation opens up new possibilities for therapeutic intervention strategies involving e.g. inhibitors of quorum sensing.
AB - Chronic P. aeruginosa infection is characterized by production of mucoid alginate and formation of microcolonies (biofilm) as seen in the lungs of cystic fibrosis patients. Oxygen radicals produced by the inflammatory response polymorphonuclear leucocytes induces the alginate production. The biofilm mode of growth is the survival strategy of environmental bacteria and alginate biofilms are also protected against antibiotics and against the immune response in the lungs of the patient. Quorum sensing is important for early and mature biofilm formation and also for the severity of the infection. The new knowledge of the mechanisms involved in biofilm formation opens up new possibilities for therapeutic intervention strategies involving e.g. inhibitors of quorum sensing.
KW - Alginates
KW - Anti-Bacterial Agents/therapeutic use
KW - Anti-Inflammatory Agents/therapeutic use
KW - Biofilms/drug effects
KW - Chronic Disease
KW - Cystic Fibrosis/complications
KW - Drug Resistance, Bacterial/immunology
KW - Glucuronic Acid/immunology
KW - Hexuronic Acids/immunology
KW - Humans
KW - Pneumonia, Bacterial/microbiology
KW - Pseudomonas Infections/complications
KW - Pseudomonas aeruginosa/immunology
U2 - 10.1016/s1569-1993(02)00104-2
DO - 10.1016/s1569-1993(02)00104-2
M3 - Review
C2 - 15463822
SN - 1569-1993
VL - 1
SP - 249
EP - 254
JO - Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
JF - Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
IS - 4
ER -